Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
STRYKER PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


20 mayo 2013

CE Mark Granted for Sequent Medical’s Web SL Family of Neurovascular Aneurysm Embolization Devices

Endovascular Today

Sequent Medical, Inc. (Aliso Viejo, CA) announced that it has received CE Mark approval for the SL (single-layer) family of Web aneurysm embolization devices and has commenced a controlled release of these new models in select neurovascular centers in Europe. The SL family offers a lower profile and excellent navigability that will enable physicians to treat a broader range of aneurysms with the Web platform, the company stated.

20 mayo 2013

Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices

Healthcare Sales & Marketing Network

Sequent Medical, Inc. announced today that it has received CE mark for the SL ("Single Layer") family of WEB® Aneurysm Embolization Devices, and has commenced a controlled release of these new models in select neurovascular centers in Europe. The SL family offers a lower profile and superior navigability that will enable physicians to treat a broader range of aneurysms with the WEB platform.

09 mayo 2013

CREST Substudy Finds Balloon Angioplasty After Carotid Stenting Reduces Restenosis Risk

Endovascular Today

The Society for Cardiovascular Angiography and Interventions (SCAI) announced the presentation of a CREST (Carotid Revascularization Endarterectomy versus Stenting Trial) substudy at the SCAI 2013 scientific sessions in Orlando, Florida. The objective of this substudy was to evaluate whether undergoing angioplasty after carotid stenting increases the risk of complications such as stroke.

03 mayo 2013

Study Compares the Use of Rescue Therapies During Endovascular Treatment for Cerebral Aneurysms

Endovascular Today

May 3, 2013—Using a large, multihospital database, investigators sought to evaluate the morbidity and mortality associated with the use of intra-arterial or intravenous thrombolytic agents or glycoprotein IIb/IIIa inhibitors (GPI) to treat acute intraprocedural thrombus formation during endovascular cerebral aneurysm treatment. Waleed Brinjikji, MD, et al recently published the findings online ahead of print in Stroke.

01 mayo 2013

Study Shows Urinary Biomarkers May Help Detect Pediatric Intracranial AVMs

Endovascular Today

May 1, 2013—The American Association of Neurological Surgeons (AANS) announced results from a recent study conducted by investigators from Boston Children’s Hospital that showed that the urinary levels of hepatocyte growth factor (HGF) could serve as a biomarker capable of detecting the presence of arteriovenous malformations (AVMs). Edward Robert Smith, MD, presented data from the study at the AANS annual scientific meeting, which was held April 27 to May 1 in New Orleans, Louisiana. The presentation was titled Noninvasive Urinary Biomarkers Can Detect the Presence of Intracranial Arteriovenous Malformations.

01 marzo 2013

Studies Published in Pain Medicine Demonstrate Effectiveness of Minimally-Invasive Cooled Radiofrequency Treatment for Low Back Pain

Healthcare Sales & Marketing Network

Kimberly-Clark today announced the publication of two separate studies that achieved positive outcomes following use of cooled radiofrequency (RF) to treat discogenic and sacroiliac joint (SIJ) pain in the low back. The studies evaluated Kimberly-Clark s TransDiscal Cooled Radiofrequency System and SInergy Cooled Radiofrequency System and demonstrated that both treatment options provided patients who suffer from chronic low back pain with much-needed pain relief and improved quality of life benefits. Results were published in Pain Medicine, the official journal of the American Academy of Pain Medicine, the Faculty of Pain Medicine of the Australian and New Zealand College of Anesthetists, and the International Spine Intervention Society

28 febrero 2013

InVivo Therapeutics Submits Updated IDE to FDA to Begin Spinal Cord Injury Human Study

Healthcare Sales & Marketing Network

InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced the Company has submitted an updated Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) requesting permission to begin human studies in order to test its biopolymer scaffolding for the treatment of acute SCI

19 febrero 2013

Independent Study Demonstrates Clinical Advantages Of Kiva(R) Over Balloon Kyphoplasty

Healthcare Sales & Marketing Network

An independent, prospective, randomized study of patients with vertebral compression fractures (VCFs) comparing the effectiveness of balloon kyphoplasty with the Kiva VCF Treatment System by Benvenue Medical, Inc. found that only the Kiva system significantly restored vertebral body wedge deformity, Gardner angle. The Kiva system also resulted in significantly lower rates of extravasation and cement volume than balloon kyphoplasty. The peer-reviewed study results were published online and in the Feb. 15 edition of Spine

15 febrero 2013

MRI Interventions Announces Milestone Achievements

Healthcare Sales & Marketing Network

MRI Interventions, Inc. (MRIC) announced today that the company ended 2012 having achieved the 20th installation of its ClearPoint(R) Neuro Intervention System. ClearPoint systems are in clinical use with MRI scanners from the three major manufacturers, Siemens, GE Healthcare and Philips Healthcare, as well as the two major interventional MR/OR platforms that are manufactured by IMRIS and Brainlab

04 febrero 2013

Penumbra Inc. Launches 5MAX DDC(TM) and 4MAX DDC(TM) Distal Delivery Catheters

Healthcare Sales & Marketing Network

The Penumbra 5MAX DDC and 4MAX DDC distal delivery catheters are new devices designed to simplify delivery of a wide variety of endovascular therapies to the brain. The DDC family delivers exceptional distal delivery capability via a novel advanced polymer and nitinol coil reinforcement design at the distal tip to enable easy tracking through tortuous vessels. All DDC catheters have large tapered lumens, which are compatible with most microcatheter-delivered neuro endovascular therapies today. The DDC exclusive tapered lumen design enables higher contrast flow and better visualization while maintaining the flexibility to help physicians deliver therapies more efficiently

16 octubre 2012

Stryker to Acquire Surpass Medical

Endovascular Today

October 16, 2012—Stryker Corporation (Kalamazoo, MI) announced a definitive agreement to acquire Surpass Medical, Ltd. (Tel Aviv, Israel), which is developing and commercializing next-generation flow diversion stent technology for the treatment of brain aneurysms. Surpass was founded in 2005 in Tel Aviv, with manufacturing and research and development facilities in Miramar, Florida.

16 octubre 2012

Stryker Corp. to purchase Surpass Medical for $135 million

Michigan Live

The Kalamazoo-based medical device maker announced Oct. 16 it is purchasing Surpass Medical, Ltd., for $135 million. Stryker will pay $100 million in cash for the privately held company, with up to $35 million in additional milestone payments.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.